Loading page…

Sudeep Pharma Limited (SUDEEPPHRM) · mywealthgrid

Sudeep Pharma Limited

NSE:SUDEEPPHRM BSE:SUDEEPPHRM

MaterialsChemicals & PetrochemicalsNIFTY MICROCAP 250 +1

₹1,199.8

-0.5%1 Oct close

Mkt cap

₹13,546 Cr

Watch Alert Compare

About

Sudeep Pharma Limited is a specialty chemicals manufacturer in the Materials sector with a ₹12,481.66 Cr market cap. It demonstrates strong operational consistency with 34–37% operating margins across recent quarters and maintains a conservative balance sheet (D/E 0.17), positioning it as a capital-efficient player in the chemicals and petrochemicals industry.

Face value: ₹1

Market cap

₹13,546 Cr

P/E

101.7×

P/B

15.3×

Dividend yield

0.1%

ROE

25.2%

ROCE

31.1%

Debt / equity

0.17

OPM

34.6%

EPS (TTM)

₹11.8

Book value

₹78.2

52-week high

—

52-week low

Key insights

Company research notes and source-linked reviews

Key risks

Extremely high valuation: PE of 93.74 leaves minimal margin of safety if earnings growth disappoints relative to current price
Revenue reporting complexity: Quarterly standalone revenue ranges ₹80–182 Cr; verify whether this reflects reporting structure, business cyclicality, or actual operational volatility
Shareholder concentration: Promoter holding of 76.15% with public float below 7% limits liquidity and external shareholder oversight
Earnings history unavailable: 1y return is n/a; verify historical earnings growth trajectory and verify guidance from recent earnings call (2026-08-05) to justify valuation

Generated analysis · source review pending

Growth drivers

High ROE of 25.16% enables reinvestment of earnings for organic growth without external capital requirements
Quarterly net profit of ₹26–48 Cr provides cash generation capacity for expansion or strategic acquisitions
Conservative D/E ratio of 0.17 offers financial flexibility to deploy leverage if management identifies attractive growth opportunities
Specialty chemicals subsector carries structural demand drivers; verify end-market trends, export potential, and the company's competitive positioning

Generated analysis · source review pending

205 historical price candles were omitted because the exchange source has not been verified.

₹1,199.8+0.4%1Y

Quick read

rule-based

Pros

+Strong return on equity of 26.7% (3-yr avg)
+High return on capital employed of 32.9%
+Healthy operating margin of 34.6%
+Comfortable interest coverage of 31×
+High promoter holding of 76.2% with no pledge

Cons

−Expensive at 101.7× trailing earnings
−Trading at 15.3× book value

Research score

Structured signal from quality, growth, valuation and momentum.

46/100

Business quality: 92
Valuation: 0

Revenue & net profit

₹ crore, by fiscal year

RevenuePAT

Margins

% of revenue, by fiscal year

OPMPAT margin

Peers

Comparable companies from the narrowest available industry classification.

Part ofNIFTY MICROCAP 250 NIFTY TOTAL MARKET

Screen this industry Compare top 5 side-by-side

Company	Mkt Cap	EV	Revenue	EBITDA	OPM	PAT	NPM	ROCE	ROE	WC Days
Gujarat Fluorochemicals LimitedFLUOROCHEMFLUOROCHEM	₹47,713 Cr	₹49,912 Cr	₹5,303 Cr	₹1,375 Cr	25.8%	₹615 Cr	11.5%	11.1%	7.6%	401
Navin Fluorine International LimitedNAVINFLUORNAVINFLUOR	₹41,740 Cr	₹42,967 Cr	₹3,634 Cr	₹1,232 Cr	32.6%	₹790 Cr	20%	21.6%	20.1%	61
Aether Industries LimitedAETHERAETHER	₹22,161 Cr	₹22,603 Cr	₹1,224 Cr	₹384 Cr	31.3%	₹235 Cr	19.8%	13.2%	9.4%	330
Atul LimitedATULATUL	₹17,231 Cr	₹17,411 Cr	₹6,643 Cr	₹1,189 Cr	16.4%	₹704 Cr	11%	14.1%	11.5%	70
Aarti Industries LimitedAARTIINDAARTIIND	₹16,869 Cr	₹21,790 Cr	₹9,012 Cr	₹1,337 Cr	14.1%	₹531 Cr	5.1%	8.8%	7.3%	54
Fine Organic Industries LimitedFINEORGFINEORG	₹15,752 Cr	₹15,797 Cr	₹2,472 Cr	₹535 Cr	20.4%	₹438 Cr	17.6%	21.6%	16.8%	113
Basf India LimitedBASFBASF	₹14,796 Cr	₹14,796 Cr	₹16,177 Cr	₹952 Cr	4.4%	₹643 Cr	2.8%	14%	11.1%	40
Privi Speciality Chemicals LimitedPRIVISCLPRIVISCL	₹13,970 Cr	₹14,980 Cr	₹2,671 Cr	₹666 Cr	25.2%	₹342 Cr	12.4%	27.7%	25.2%	158
Sudeep Pharma LimitedSUDEEPPHRMSUDEEPPHRM	₹13,546 Cr	₹13,694 Cr	₹676 Cr	₹233 Cr	34.6%	₹133 Cr	27.1%	31.1%	25.2%	366
Anupam Rasayan India LimitedANURASANURAS	₹13,243 Cr	₹15,058 Cr	₹2,535 Cr	₹563 Cr	22.2%	₹175 Cr	9.4%	9.1%	5.5%	377
Vinati Organics LimitedVINATIORGAVINATIORGA	₹12,528 Cr	₹12,528 Cr	₹2,381 Cr	₹665 Cr	29.4%	₹448 Cr	19.9%	18.8%	14.9%	152
Elantas Beck India LimitedELANTASELANTAS	₹10,644 Cr	₹10,644 Cr	₹778 Cr	₹147 Cr	20.3%	₹136 Cr	17.4%	20.6%	15.8%	70

Loading peers…

Financials

Reported profit and loss, balance sheet, cash flow and growth history.

Annual Quarterly

Consolidated Standalone

Consolidated figures · ₹ crore

₹ Cr	Mar 2025	Mar 2026
	502	642
COGS	—	227
Gross profit	—	415
	312	193
	190	222
OPM %	37.8%	34.6%
Depreciation	11	15
Interest	6	8
	9	29
Profit before tax	183	228
Tax	44	54
Tax %	24.1%	23.6%
	139	174
PAT margin %	27.6%	27.1%
EPS (₹)	12.8	15.5
EPS adjusted (₹)	14.3	15.3
	0%	9.7%
Annual report	—	Annual report for Mar 2026

₹ Cr	Mar 2025	Mar 2026
Equity capital	10	11
Reserves	481	872
Minority interest	2	15
	135	148
	89	129
Total equity & liabilities	717	1,175
	246	292
CWIP	88	178
Investments	0	0
	383	704
Total assets	717	1,175

₹ Cr	Mar 2026
	70
	-327
	247
Net cash flow	-10
Free cash flow	-49
CFO / Operating profit %	31.3%

Compounded sales growth

7 years: —
5 years: —
3 years: —
1 year: 28%

Compounded profit growth

7 years: —
5 years: —
3 years: —
1 year: 26%

Return on equity

7 years: —
5 years: —
3 years: —
Last year: 19%

Segment results

As reported in NSE results XBRL. Segment result is before tax and finance costs. ROCE uses that annual result divided by segment assets less liabilities.

Source XBRL ↗

Latest reported period · 31 Mar 2026 · ₹ crore

Segment	Revenue	Result	Assets	Liabilities	Capital employed	ROCE %
Pharmaceutical, Food and Nutrition	362.64	113.52	727.21	217.88	509.33	22.29
Speciality Ingredients	279.62	93.58

Loading financials…

Ratios

Annual operating, return, leverage and working-capital ratios.

Consolidated Standalone

Consolidated figures

Ratio	Mar 2025	Mar 2026
Margins
Gross margin %	—	64.6%
EBITDA margin %	37.8%	34.6%
EBIT margin %	35.7%	32.2%
PAT margin %	27.6%	27.1%
Working capital
Receivable days	135	129
Inventory days	151	347
Payable days	3	110
NWC days	283	366
Leverage
Current ratio	2.43	3.09
Debt to EBITDA	0.71	0.67
Debt to equity	0.28	0.17
Interest coverage	32.3	31
Asset turnover	0.7	0.55
Return ratios
Return on assets %	19.3%	14.8%
Return on capital employed %	34.8%	31.1%
Return on equity %	28.3%	19.7%

Derived from reported annual statements. ROCE uses EBIT over capital employed (total assets less current liabilities). Day counts average the opening and closing balance; receivables turn on revenue, inventory and payables on cost of goods sold.

Loading ratios…

Shareholding

Quarterly ownership, named holders, insider transactions and disclosed deals.

Quarterly Annual

Every quarter filed · % of equity

Holder (%)	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	76.15%	76.15%	76.15%	76.15%
	1.54%	1.67%	1.55%	1.81%
	14.76%	17.6%	18.11%	15.65%
Government	0%	0%	0%	0%
	7.55%	4.58%	4.19%	6.39%
No. of shareholders	2,17,982	43,599	36,503	35,695

Promoter holding up 0 percentage points since Sep 2025.

20 deals · 28 Nov 2025 – 24 Jul 2026

Date	Client	Type	Venue	Side	Quantity	Price	Value
24 Jul 2026	SBI MUTUAL FUND	Block	NSE	Buy	20,00,000	₹800.00	₹160.00 Cr
24 Jul 2026	SBI MUTUAL FUND	Bulk	NSE	Buy	20,00,000	₹800.00	₹160.00 Cr
24 Jul 2026	NUVAMA CROSSOVER OPPORTUNITIES FUND - SERIES III	Block	NSE	Sell	10,60,000	₹800.00	₹84.80 Cr
24 Jul 2026	NUVAMA CROSSOVER OPPORTUNITIES FUND - SERIES III	Bulk	NSE	Sell	10,60,000	₹800.00	₹84.80 Cr
24 Jul 2026	NUVAMA CROSSOVER OPPORTUNITIES FUND - SERIES IIIA	Block	NSE	Sell	9,40,000	₹800.00	₹75.20 Cr
24 Jul 2026	NUVAMA CROSSOVER OPPORTUNITIES FUND - SERIES IIIA	Bulk	NSE	Sell	9,40,000	₹800.00	₹75.20 Cr
28 Nov 2025	JUNOMONETA FINSOL PRIVATE LIMITED	Bulk	NSE	Buy	19,75,787	₹768.67	₹151.87 Cr
28 Nov 2025	JUNOMONETA FINSOL PRIVATE LIMITED	Bulk	NSE	Sell	19,40,610	₹769.09	₹149.25 Cr
28 Nov 2025	IRAGE BROKING SERVICES LLP	Bulk	NSE	Sell	9,66,253	₹763.06	₹73.73 Cr
28 Nov 2025	IRAGE BROKING SERVICES LLP	Bulk	BSE	Buy	8,41,889	₹761.55	₹64.11 Cr

1–10 of 20

1 / 2

Mr. BHAYANI SUJIT JAYSUKHExecutive Director-Chairperson
Mr. SHANIL SUJIT BHAYANIExecutive Director
Mr. AJAY SHRIRANG KANDELKARExecutive Director
Mr. MILIN KAIMAS MEHTANon-Executive - Non Independent Director
Mr. SAMARESH PARIDANon-Executive - Independent Director
Mr. RAGHUNANDAN SATHYANARAYAN RAONon-Executive - Independent Director
Mr. SUJIT GULATINon-Executive - Independent Director
Ms. RESHMA SURESH PATELNon-Executive - Independent Director
Mr. Milin MehtaNon - Executive Non -Independent Director
Dimple Ashwinbhai MehtaCompany Secretary & Compliance Officer

Current officeholders as filed with BSE. A person holding two offices is listed once per office.

Loading shareholding…

F&O

Current futures and options contracts with compact option-chain pages.

Not in the F&O segment

Only about 210 stocks have listed futures and options. Contracts appear here for those, refreshed after each close.

Loading f&o…

Fund holders

Mutual-fund schemes that disclosed a holding in the company.

Portfolio month

Schemes holding

across 5 fund houses

Held by these funds

5.02%

of the company's equity

All mutual funds

5.47%

shareholding pattern, Jun 2026

Portfolios as of

August 2026

compared with July 2026

13 schemes · 5 fund houses

		Shares
Small Cap Fund	Axis Mutual Fund	20.02 L	242.19	0.77%	1.773%	-0
Healthcare Opportunities Fund	SBI Mutual Fund	13.6 L	164.52	2.84%	1.205%	-0
MNC Fund	SBI Mutual Fund	6.88 L	83.17	1.24%	0.609%	-0
Comma Fund	SBI Mutual Fund	6.88 L	83.17	6.73%	0.609%	-0
RETIREMENT BENEFIT FUND - AGGRESSIVE PLAN	SBI Mutual Fund	4.38 L	52.93	1.63%	0.388%	+21
RETIREMENT BENEFIT FUND - AGGRESSIVE HYBRID PLAN	SBI Mutual Fund	1.88 L	22.77	1.36%	0.167%	+736
TRUSTMF Small Cap FundNEW	Trust Mutual Fund	1.81 L	21.91	0.64%	0.16%	—
(Investment Manager for Motilal Oswal Mutual Fund)	Motilal Oswal Mutual Fund	65,003	7.86	0.32%	0.058%	-1,448

1–8 of 13

1 / 2

Loading fund holders…

Documents

Annual reports, exchange filings, offer documents, ratings and earnings-call material.

Announcements

Annual reports

Annual Report FY2026from bse Summary

Investor Presentation and earnings call

Aug 2026Transcript AI Summary PPTREC
May 2026Transcript AI Summary PPT

Documents link to external sources (exchange filings, company investor pages).

Loading documents…

Events

Upcoming dates and the company’s corporate-action history.

1

Final dividend23 Jul 2026 · ex-date₹1.5

1

Board meeting to consider results4 Aug 2026

1

Earnings call5 Aug 2026call

Loading events…

Announcements

Latest exchange announcements, filings and downloadable documents.

1 month 3 months 6 months 1 year All

13 announcementsExport CSV

22 Sept 2026, 12:43 pmCompany Update

Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

Analyst / Investor Meet PDF

Loading announcements…

Ratio	Mar 2025	Mar 2026
Margins
Gross margin %	—	64.6%
EBITDA margin %	37.8%	34.6%
EBIT margin %	35.7%	32.2%
PAT margin %	27.6%	27.1%
Working capital
Receivable days	135	129
Inventory days	151	347
Payable days	3	110
NWC days	283	366
Leverage
Current ratio	2.43	3.09
Debt to EBITDA	0.71	0.67
Debt to equity	0.28	0.17
Interest coverage	32.3	31
Asset turnover	0.7	0.55
Return ratios
Return on assets %	19.3%	14.8%
Return on capital employed %	34.8%	31.1%
Return on equity %	28.3%	19.7%

Date	Category	Subject	Filing
22 Sept 2026, 12:43 pm	Company Update Analyst / Investor Meet	Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation	PDF
16 Sept 2026, 11:13 am	Company Update Analyst / Investor Meet	Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation	PDF
11 Aug 2026, 4:08 pm	Company Update Earnings Call Transcript	Announcement under Regulation 30 (LODR)-Earnings Call Transcript	PDF
4 Aug 2026, 9:34 pm	Company Update Investor Presentation	Announcement under Regulation 30 (LODR)-Investor Presentation	PDF
29 Jul 2026, 10:18 am	Company Update General	Disclosures under Reg. 29(1) & 29(2) of SEBI (SAST) Regulations, 2011	PDF
27 Jul 2026, 12:03 pm	Company Update Analyst / Investor Meet	Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation	PDF
25 Jul 2026, 12:52 pm	Board Meeting	Board Meeting Intimation for Adoption Of Unaudited Financials (Standalone & Consolidated) For The Quarter Ended 30Th June 2026	PDF
11 Jul 2026, 12:56 pm	Company Update Newspaper Publication	Announcement under Regulation 30 (LODR)-Newspaper Publication	PDF

Sudeep Pharma Limited

About

Key insights

Key risks

Growth drivers

Quick read

Pros

Cons

Research score

Revenue & net profit

Margins

Peers

Financials

Profit & loss

Balance sheet

Cash flow

Compounded returns

Compounded sales growth

Compounded profit growth

Return on equity

Segment results

Ratios

Ratio timeline

Shareholding

Quarterly record

Bulk & block deals

Board and management

F&O

Not in the F&O segment

Fund holders

Documents

Announcements

Annual reports

Investor Presentation and earnings call

Events

Dividends1

Board meetings1

Other corporate actions1

Announcements

Dividends1

Board meetings1

Other corporate actions1

Ratio timeline

Not in the F&O segment

Announcements

Annual reports

Investor Presentation and earnings call

Quarterly record

Bulk & block deals

Board and management

Profit & loss

Balance sheet

Cash flow

Compounded returns

Compounded sales growth

Compounded profit growth

Return on equity

Segment results

Inter Segment Revenue · revenue

1

1

1

1

1

1